Areas of Consensus and Differences Among a Panel of Experts on the Optimal Use of Newly Approved Agents to Treat Multiple Myeloma (MM): Results from an Annually Updated Online Decision Support Tool

• Published in: Blood Vol. 128; no. 22; p. 2379
• Main Authors: Quill, Timothy A, Rosenthal, Kristen M, Kumar, Shaji, Lentzsch, Suzanne, Lonial, Sagar, Roodman, G. David, Obholz, Kevin L, Anderson, Kenneth C.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 02.12.2016

Background In 2015, the FDA approved 5 new agents and/or combination regimens for the treatment of patients with relapsed/refractory (R/R) MM. In addition, new clinical data support using new regimens in the first-line setting. This rapid expansion of available treatment options has greatly increase...